"The KPOCT physicians honored exemplify the best in terms of knowledge, energy, and effort to ensure that KPNC patients with cancer receive the highest quality treatment and the best chances for survival."
Michael A. Horberg, MD
Chair, TPMG/KPNC
Central Research Committee
Oncology
East Bay Area
Recognized for their leadership of the Kaiser Permanente Oncology Clinical Trials Program (KPOCT). The oncologists have among the highest number of patient enrollments in clinical trials within TPMG — over 100 patients each — contributing greatly to the success of the clinical trials program in Northern California.
More than 100 TPMG physicians and 40 research personnel facilitate participation in clinical trials. There are approximately 40 trials open for patient accrual at any given time. Since its inception 15 years ago, KPOCT has administered 264 clinical trials, enrolling more than 3700 patients. Currently, there are over 1700 Kaiser Permanente patients receiving treatment or on active follow-up for twelve different types of cancer.
Among 200 US and Canadian institutions, KPOCT is the largest contributor to the National Surgical Adjuvant Breast and Bowel Project (NSABP), which includes large-scale trials for the treatment and prevention of breast cancer.
In 2007, KPOCT received the American Society of Clinical Oncology’s Clinical Trials Award in recognition of its dedication to the advancement of cancer treatments through clinical trials. Each year, more than 300 Northern California Kaiser Permanente patients enter clinical trials, enabling them to receive promising new treatments prior to FDA approval.